- Home
- DXR vs BNR Comparison
DXR vs BNR Comparison
Compare DXR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- BNR
- Stock Information
- Founded
- DXR 1970
- BNR 2014
- Country
- DXR United States
- BNR China
- Employees
- DXR N/A
- BNR N/A
- Industry
- DXR Medical/Dental Instruments
- BNR Medical Specialities
- Sector
- DXR Health Care
- BNR Health Care
- Exchange
- DXR Nasdaq
- BNR Nasdaq
- Market Cap
- DXR 46.9M
- BNR 38.3M
- IPO Year
- DXR N/A
- BNR 2020
- Fundamental
- Price
- DXR $10.60
- BNR $7.48
- Analyst Decision
- DXR Strong Buy
- BNR
- Analyst Count
- DXR 1
- BNR 0
- Target Price
- DXR $25.00
- BNR N/A
- AVG Volume (30 Days)
- DXR 77.8K
- BNR 57.1K
- Earning Date
- DXR 01-01-0001
- BNR 08-25-2025
- Dividend Yield
- DXR N/A
- BNR N/A
- EPS Growth
- DXR 86.16
- BNR N/A
- EPS
- DXR 0.11
- BNR N/A
- Revenue
- DXR $119,714.00
- BNR $72,112,038.00
- Revenue This Year
- DXR N/A
- BNR $136.32
- Revenue Next Year
- DXR N/A
- BNR N/A
- P/E Ratio
- DXR $97.52
- BNR N/A
- Revenue Growth
- DXR N/A
- BNR 0.53
- 52 Week Low
- DXR $6.55
- BNR $2.18
- 52 Week High
- DXR $11.38
- BNR $9.48
- Technical
- Relative Strength Index (RSI)
- DXR 57.66
- BNR 65.71
- Support Level
- DXR $10.01
- BNR $6.66
- Resistance Level
- DXR $11.38
- BNR $7.15
- Average True Range (ATR)
- DXR 0.74
- BNR 0.65
- MACD
- DXR 0.06
- BNR 0.00
- Stochastic Oscillator
- DXR 65.64
- BNR 87.14
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.